Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

Inclusion Criteria: * Meets the diagnostic criteria for type 2 diabetes(1999 WHO criteria). * Meets the diagnostic criteria for non-alcoholic fatty liver disease (2018 Chinese Medical Association Treatment Guidelines ), and liver ultrasound showed moderate or higher fatty liver. * Metformin monotherapy for 3 months * 8 years old ≤ age ≤ 70 years old; * Have a good follow-up compliance, with follow-up months ≥ 24 weeks; Exclusion Criteria: Non-type 2 diabetes: type 1 diabetes, gestational diabetes, or other specific types of diabetes; * Diabetes patients with acute and chronic complications and serious infections; Pregnant and lactating women; * Those who have allergies or toxic side effects or contraindications to canagliflozin, pioglitazone and other drugs; * Active sexually transmitted diseases such as viral hepatitis, AIDS and syphilis, and infectious diseases such as tuberculosis; * Have a weight change of more than 10% in the 3 months prior to screening; * Have used other drugs that may affect blood glucose metabolism in the past 2 months, including systemic glucocorticoids (except inhalation or topical use), growth hormone, etc.; * Have used any sodium-glucose cotransporter-2 (SGLT-2) inhibitor or thiazolidinediones in the 3 months prior to screening; * History of more than 2 severe hypoglycemic episodes in the past 1 year; * History or condition of any of the following: decompensated cardiac insufficiency (NYHA class III or IV); history of unstable angina, myocardi…